Stop wasting hours on dense SEC filings. Get AI-powered summaries of any SEC Filings in seconds. Understand key insights and risks, fast.
Currently we only process Form 8-K, 6-K, 3, 4, 144, Schedule 13D and Schedule 13G. We will support more forms in the future.
Filter by Form Type:
Industry:Biotechnologyβ
2026-04-02GHRS3Julie Ryan's Form 3 Filing for GH Research PLC - Initial Statement of Beneficial Ownership
This is a Form 3 filing by Julie Ryan, VP of Finance at GH Research PLC, disclosing her initial statement of beneficial ownership in the company. The filing reports ownership of four separate share option grants totaling 247,987 ordinary shares. The options have varying exercise prices and vesting schedules, with expir...
Small CapBiotechnology
2026-04-02GHRS3GH Research PLC CEO Velichka Valcheva Form 3 Filing and Power of Attorney
This SEC Form 3 filing reports the initial beneficial ownership of GH Research PLC (ticker: GHRS) by CEO Velichka Valcheva. The filing discloses four separate share option grants with different vesting schedules and exercise prices. Valcheva was granted options to purchase 685,000 ordinary shares in total, with exercis...
Small CapBiotechnology
2026-04-02GHRS3Magnus Halle Form 3 Filing for GH Research PLC Share Options and Ownership
This Form 3 filing reports the initial beneficial ownership of Magnus Halle, Managing Director of GH Research PLC (GHRS). Halle owns 118,354 ordinary shares directly. Additionally, he holds three separate share option grants: 17,500 options exercisable at $0.025 expiring April 27, 2030; 150,000 options exercisable at $...
Small CapBiotechnology
2026-04-02GHRS3Ownership Filing for GH Research PLCMEDIUM
This filing details the ownership of GH Research PLC by Dermot John Hanley, who is a director of the company. As of March 18, 2026, Hanley directly owns 2,432 ordinary shares. The filing also discloses various share options granted to Hanley, with exercise prices of $0.025. These options have different vesting and expi...
Small CapBiotechnology
2026-04-02GH Research PLC3Magnus Halle Form 3 Filing for GH Research PLC Share Options and OwnershipDuplicate
This Form 3 filing reports the initial beneficial ownership of Magnus Halle, Managing Director of GH Research PLC (GHRS). Halle owns 118,354 ordinary shares directly. Additionally, he holds three separate share option grants: 17,500 options exercisable at $0.025 expiring April 27, 2030; 150,000 options exercisable at $...
Small CapBiotechnology
2026-04-02GH Research PLC3Ownership Filing for GH Research PLCDuplicateMEDIUM
This filing details the ownership of GH Research PLC by Dermot John Hanley, who is a director of the company. As of March 18, 2026, Hanley directly owns 2,432 ordinary shares. The filing also discloses various share options granted to Hanley, with exercise prices of $0.025. These options have different vesting and expi...
Small CapBiotechnology
2026-04-02AUPH3Power of Attorney FilingMEDIUM
This filing details a Power of Attorney granted by Michael S. Hearne, Chief Financial Officer of Aurinia Pharmaceuticals Inc., to Stephen Robertson. The Power of Attorney authorizes Robertson to act on Hearne's behalf for all Section 16(a) and Rule 144 filings with the SEC, including obtaining EDGAR credentials, managi...
Mid CapBiotechnology
Sponsored